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REVIEW
Unraveling cellular pathways contributing to drug-induced liver injury by dynamical
modeling
Isoude A. Kuijper, Huan Yang, Bob Van De Water and Joost B. Beltman
Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
ABSTRACT
Introduction: Drug-induced liver injury (DILI) is a significant threat to human health and a major
problem in drug development. It is hard to predict due to its idiosyncratic nature and which does
not show up in animal trials. Hepatic adaptive stress response pathway activation is generally observed
in drug-induced liver injury. Dynamical pathway modeling has the potential to foresee adverse effects
of drugs before they go in trial. Ordinary differential equation modeling can offer mechanistic insight,
and allows us to study the dynamical behavior of stress pathways involved in DILI.
Areas covered: This review provides an overview on the progress of the dynamical modeling of stress
and death pathways pertinent to DILI, i.e. pathways relevant for oxidative stress, inflammatory stress,
DNA damage, unfolded proteins, heat shock and apoptosis. We also discuss the required steps for
applying such modeling to the liver.
Expert opinion: Despite the strong progress made since the turn of the century, models of stress
pathways have only rarely been specifically applied to describe pathway dynamics for DILI. We argue
that with minor changes, in some cases only to parameter values, many of these models can be
repurposed for application in DILI research. Combining both dynamical models with in vitro testing
might offer novel screening methods for the harmful side-effects of drugs.
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1. Introduction
Drug-induced liver injury (DILI) is the most frequent cause of
acute liver failure [1]. Almost half of the cases of such liver
failure in the United Kingdom and United States are attributed
to DILI [1,2]. This problem represents a huge financial burden
to the pharmaceutical industry, because new medication is
often found to be causing DILI at a very late drug develop-
ment stage, such as when a drug is already in its clinical test
phase or, even worse, when the drug is already on the market.
DILI is the most common reason for drug withdrawal [3] and
can be separated into intrinsic or idiosyncratic liver injury.
Intrinsic liver injury is dose dependent and predictable when
given in sufficiently high dose. The mechanism behind intrin-
sic DILI frequently involves exposure of cells to an excess of
stress so that a cell either dies after activating highly regulated
cell death pathways (i.e. apoptosis) or directly dies because it
cannot deal with the high exposure (i.e. necrosis). In contrast,
idiosyncratic liver injury is unpredictable and has a low inci-
dence rate (1:100,000 users) [4]. The mechanisms causing
idiosyncratic DILI are highly complex and poorly understood.
Current techniques that include animal testing or simple in
vitro tests are insufficient to predict the idiosyncratic DILI
properties of drugs, although many efforts to enhance in
vitro testing have been started [5] (e.g. the IMI MIP-DILI pro-
ject). In 2007, the National Research Council Committee of
Toxicity and Assessment of Environmental Agents presented
a new vision and strategic plan for toxicity testing [6]. In short,
the suggested approach involves a combination of dynamic in
vitro data and computational modeling.
Many types of models are of interest for the understanding
and prediction of DILI, including quantitative adverse outcome
pathways (qAOPs), cheminformatic models, pharmacokinetic–
pharmacodynamic (PK–PD) modeling, and dynamical pathway
modeling with ordinary differential equation (ODE) models.
Excellent reviews have recently been published about adverse
outcome pathways [7], multi-scale computational models [8],
and cheminformatic models [9,10].
AOPs describe the path from a molecular initiation event to
an adverse outcome, through a number of key events. These
key events can occur on different biological levels (subcellular,
cellular, tissue, organ, individual, and population level)
(Figure 1, bottom with a microscope image reproduced from
[11]). Adverse outcomes in DILI include clinical observations
such as liver fibrosis, liver steatosis, and cholestatis. The main
goal of constructing an AOP is to apply it in risk assessment
based on mechanistic reasoning [12]. qAOPs are closely
related to multi-scale computational models, which also try
to bridge different scales yet often explicitly include spatial
effects as well [8].
Cheminformatic models, i.e. in silico models based on che-
mical structure, employ existing data on chemical properties,
their key chemical substructures, effect, and interaction cap-
abilities in order to make predictions for untested chemicals.
They are helpful in the classification of potentially useful
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chemicals, or give insight in potentially harmful side effects
like DILI [13].
PK–PD modeling aims to predict exposure–response rela-
tionships. Exposure is measured as the concentration of a drug
in the plasma, and response is the effect the drug has on the
patient. Thus, the efficiency with which the drug reaches the
target location and the effect on that location are included in
these models [14].
Here, wewill review the recent progress in dynamicalmodeling
of toxicity pathways, i.e. cellular response pathways that, when
sufficiently perturbed, are expected to contribute to adverse
health effects such as liver injury [6]. These pathways can be
divided into two groups, i.e. cellular stress and death pathways.
Death pathways are networks involved in the process of highly
regulated cell death, whereas stress pathways are networks cap-
able of responding quickly to a threat, resulting in the production
of proteins that help to remove the threat or minimize damage.
Dynamical modeling aims to describe these cellular processes as a
network of biochemical reactions, thus representing the biological
processes schematically and quantitatively. The biochemical
reactions are formulated as ODEs such that they obey kinetic
principles like the law of mass action, Michaelis–Menten kinetics,
or cooperativity modeled by a Hill equation [15,16]. Such models
can offer mechanistic insights about the molecular processes
within a pathway. For example, the ODE models can be used to
investigate the potential stable states of the system and to study
what happens when a pathway is perturbed. If the system in that
case evolves toward a stable malfunctioning state, this may be
relevant for DILI-related disease progression. Using ODE models,
one can furthermore test hypotheses about the network structure
and how that structure affects the resulting dynamics of a cellular
system [17]. The expected impact of specific biochemical interac-
tions on the dynamics can be evaluated within models, which
would be much harder or even impossible by experimental work.
This is because the mechanisms involved are often highly non-
linear and include multiple feedback loops, which makes inter-
pretation of experimental data complicated and sometimes
counterintuitive. The aim of this review is to assess recent progress
in mechanistic dynamical modeling of pathways contributing to
DILI and highlight its biological relevance.
2. Stress and death pathways
Technological developments in molecular biology, e.g. next-
generation sequencing and high-throughput measurements,
have enabled significant advances in the field of systems
biology. For example, it has resulted in new insights into
formerly unknown key network elements. Indeed, the applica-
tion of cluster analysis on ‘big data’ has given a better under-
standing of the complex network of the cell. However, this
large amount of information can be daunting, and deciding
which pathways and players one should focus on becomes an
increasingly difficult question. This is because cluster analysis
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provides an overview of which players might be involved, but
it does not directly provide information about their causal
relations and whether direct or indirect interactions occur.
Combined experimental and computational approaches are
required to solve this problem [18,19].
In this review, we focus on the recent modeling progress
with respect to cellular stress and death pathways that are
suspected to be related to DILI, aiming to obtain a mechanistic
understanding of the functioning of the individual pathways.
Stress pathways try to repair a ‘controlled variable’ (e.g. tem-
perature, levels of reactive oxygen species [ROS], or a stressor
itself) that is out of control [20]. To this purpose, a stress
pathway typically consists of two major components
(Figure 1, top right). First, a ‘sensor’ that picks up the stress-
induced deviation of the controlled variable, leading to activa-
tion of the transcription factor. Second, a transcription factor
that can rapidly respond, usually because under homeostatic
conditions, it is already abundantly present, albeit in an inac-
tive state. Death pathways are often instigated by a stress
pathway, so if the cell is unable to cope with the threat, it
will activate a death pathway to minimize damage to sur-
rounding cells. This avoids a spillage of the content of dead
cells over neighboring cells, which could otherwise cause a
harmful inflammatory response [21].
ODE-based models of cellular stress pathways contain system
variables and system parameters: System variables represent
concentrations of sensors, transcription factors, ‘controlled vari-
ables,’ and possibly intermediate molecules. The system para-
meters characterize molecular interactions and processes like
degradation quantitatively. Although parameters are constant
in a particular set of ODEs, their values could differ amongst
cell types or due to treatment. A general mathematical formula-
tion of ODEs is shown below the simplified control diagram of a
stress pathway in Figure 1. System variables from a stress path-
way can act as inputs to determine the fate of a cell, leading to
an integrated model that predicts the effect of various drug
treatments on cell fate.
Determining which stress and death pathways are involved
in DILI is an important part of predicting potentially harmful
compounds. The pathways discussed below, i.e. the apoptosis
pathway and the pathways dealing with oxidative stress,
inflammatory stress, DNA damage, unfolded proteins, heat
shock, are frequently implicated in DILI (for a schematic over-
view of the most important components of these pathways,
see Figure 2). However, this list is unlikely to be complete, and
the search for important indicator pathways continues.
Apart from the search for DILI-related pathways, we advo-
cate applying stress and death pathway modeling to liver cells
in order to help understand and predict DILI. The oxidative
stress and the heat-shock response (HSR) pathways have
already been applied to the liver [22,23], but to our knowl-
edge, this is not yet the case for other stress pathways. As we
will discuss below in more detail, general models or models
for different cell types or organs can be repurposed for liver
cells. In case of the inflammatory stress pathway, this is most
complicated, because collaboration of multiple cell types takes
place during an inflammatory response in the liver. Still, dyna-
mical models can give valuable mechanistic insight even if
based on only one cell type. Linking stress pathways to death
pathways can be an important step toward predicting the
severity of DILI. Such linking of pathways has been performed
in several modeling studies (discussed in more detail below)
but has not yet been applied to liver cells [24,25].
2.1. Oxidative stress pathway
The oxidative stress pathway is considered a highly important
pathway for protection against drugs that can lead to liver
injury [26]. This pathway responds to ROS and/or electrophiles.
ROS are reactive molecules containing oxygen, e.g. reactive
drug metabolites or hydrogen peroxide produced by mitochon-
dria. Under homeostatic conditions, mitochondria produce a
limited amount of ROS, but under stressful conditions, the
ROS production rate increases. In response, the oxidative stress
response pathway promotes the expression of proteins that
deactivate ROS, thus preventing further cell damage caused
by ROS. When ROS are not adequately neutralized, other stress
pathways likely also get activated because the sustained high
levels of ROS leads to DNA damage as well as build-up of
unfolded proteins due to oxidation.
2.1.1. Mechanism
Nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like
erythroid cell-derived protein with CNC homology-associated
protein 1 (Keap1) are the two major players in this stress
pathway (Figure 2(a)). Nrf2 is a transcription factor that reg-
ulates genes involved in the neutralization of oxidative stress.
Keap1, an inhibitor of Nrf2, is very sensitive to ROS and
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Figure 2. Schematic overview of the regulatory network underlying various stress pathways. To illustrate their adaptive anti-stress roles, only key players in the anti-
stress feedback of each pathway are presented in each panel. A: Oxidative stress, B: Inflammatory stress, C: Unfolded-protein stress, D: Heat-shock stress, and E: DNA-
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represents the ‘sensor’ of the pathway. ROS and electrophiles
are the ‘controlled variables’ of the system, they trigger the
pathway when their concentration exceeds a threshold, and
are managed by Nrf2-regulated genes. Recently, a theory has
been proposed regarding the mechanism explaining the func-
tioning of the Nrf2–Keap1 complex called the Hinge and Latch
theory [27]. This theory proposes that in the absence of oxi-
dative stress, Keap1 induces Nrf2 degradation, which is com-
pensated for by a high Nrf2 production rate. When Keap1
interacts with ROS, it changes its binding to Nrf2 and as a
consequence no longer promotes degradation. Therefore, Nrf2
proteins increase in numbers in the cytoplasm, move freely
into the nucleus, and activate genes that help to resolve
oxidative stress. Several important targets of Nrf2 are involved
in glutathione (GSH) synthesis, thus ensuring increased levels
of cellular GSH and hence increased neutralizing capacity for
electrophiles and ROS.
2.1.2. Modeling
Although the Nrf2 pathway is widely recognized as an impor-
tant stress pathway, only few dynamical models have been
developed for it. The first model describing the oxidative
stress pathway was constructed by Zhang et al. [20], using a
homeostatic control system as a basis. This model describes in
detail how the Nrf2 pathway responds to stress and how it
alters gene expression levels, and ultimately deals with ROS
via GSH activity. The general aim was to describe antistress
gene regulatory networks, to explore the ‘design principles’
that have evolved, and use the oxidative stress pathway as an
example. One of the design principles that was investigated
involves the response coefficient [20,28,29].
A response coefficient (also called gain) defines the sensitiv-
ity of a system variable of interest to a perturbation when the
system is at equilibrium. In the case of stress pathways, the
response coefficient indicates how much a stressor influences a
stress-relieving molecule. A high response coefficient indicates
that the stress pathway can respond fiercely to only a small
amount of a stressor. There are multiple ways to enhance the
response coefficient within a stress pathway. First, the homo-
dimerization or homo-trimerization can increase the response
coefficient, which frequently occurs for transcription factors
before they become transcriptionally active or for reactions
involving enzymatic complexes. For example, the oxidative
stress response pathway regulates two homodimer antioxidant
enzymes (GSH reductase and superoxide dismutase). Second,
the response coefficient can be enhanced by autoregulation, for
instance when a transcription factor induces its own produc-
tion. For example, Nrf2 enhances its own production and there-
fore regulates itself. Stress pathways often combine multiple
ways to enhance the response coefficient, which strongly
affects the shape of the dose response curve [20].
Zhang et al.’s [20,28,29] findings highlight why it is in
general important to apply computational modeling to stress
pathways on top of experimental work. With respect to the
application to oxidative stress in particular, their models were
subsequently adjusted to be used for renal cells, in combina-
tion with transcriptomic, proteomic, and metabolomic data
[30]. The study focused specifically on the effect that the
toxicant cyclosporine A (CsA) has on renal cells. Moreover,
Hamon et al. [30] extended the model with an in vitro PK
model creating a pharmacokinetic systems biology (PK-SB)
model [31] to take into account how much CsA actually enters
the cell.
Later, the same group [22] adapted this PK-SB model for
liver cells, by recalibrating the model using transcriptomic
data, including ROS data at different time points and litera-
ture-based GSH data. They used the compound Acetyl-para-
aminophenol (APAP) to induce cytotoxicity in a liver-on-a-chip
and compared the results with the PK-SB model. The satura-
tion of GSH metabolism led to time- and dose-dependent
APAP toxicity that was in agreement with their in vitro experi-
ments. This work demonstrates that dynamical modeling
incorporating stress pathway can be used for DILI screening.
2.2. Inflammatory stress pathway
In early DILI research, drugs were classified depending on
whether the immune system was involved in the response or
not, dividing DILI into allergic and nonallergic responses.
However, this classification turned out not to be fully accurate,
because the immune response was still involved in cases that
were previously classified as nonallergic. When a cell dies,
especially if this is not through apoptosis, it triggers the
adaptive immune response, a process called ‘sterile inflamma-
tion.’ The inflammatory stress response has been suggested to
play a role in the unpredictability of DILI, and the nonlinearity
of drug response curves [1,32,33].
The inflammatory response gets activated when innate
immune cells detect an infection or tissue injury. To commu-
nicate to the surrounding cells that there is an infection or
damaged tissue, cytokines such as tumor necrosis factor α
(TNFα) is released. These pro-inflammatory cytokines are
detected by receptors on both immune cells and hepatocytes.
In both cell types, this causes cytokine-induced signaling.
Within immune cells, this represents one of the required sig-
nals for activation of the adaptive immune response, which
induces a classical allergic DILI response [34].
2.2.1. Mechanism
The main transcription factor of the pro-inflammatory
response pathway is nuclear factor kappa-light-chain-enhan-
cer of activated B cells (NF-κB) (Figure 2(b)). To be precise, NF-
κB is a family of dimeric transcription factors, of which the
RelA(p65):p50 complex is the most common. They regulate
genes that in turn regulate a wide variety of processes such as
cell division, apoptosis, and inflammation [35]. Under homeo-
static conditions, the NF-κB dimers are bound to one of multi-
ple possible NF-κB inhibitor (IκB) isoforms (the sensor), which
keeps them in the cytoplasm. When the pathway becomes
activated, the enzyme IκB kinase (IKK) phosphorylates IκB,
which as a result becomes targeted for degradation by the
proteasome. The freed NF-κB can then migrate into the
nucleus and activate many genes involved in a wide variety
of functions, ranging from inter- and intracellular communica-
tion, changes in cell behavior and cell fate. Some of these
genes are responsible for positive (TNFα) or negative feedback
loops (IκB isoforms and the A20 inhibitor of IKK).
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2.2.2. Modeling
Compared to oxidative stress, the inflammatory stress path-
way is much more extensively modeled and investigated.
Williams et al. have already written excellent reviews about
the progress on this subject [36,37]. Therefore, we will here
discuss only some highlights.
NF-κB pathway modeling started at the beginning of this
century by Carlotti et al. [38] who developed a simple model to
quantify the shuttling speed of NF-κB and IκB in and out of the
nucleus. A more complex pathway model was developed by
Hoffman et al. [39] that consisted of a set of 24 ODEs. Their
study focused on the regulation of three IκB isoforms (IκBα,
IκBβ, and IκBε), exhibiting distinct functions. Employing a com-
bination of mouse experiments and modeling, they showed that
IκBα, through its strong negative feedback, is responsible for a
rapid NF-κB response and a highly oscillatory profile, while IκBβ
and ε respond more slowly and are responsible for the dampen-
ing of the oscillations. In follow-upwork, Hoffman and colleagues
have focused on different aspects of the pathway. For example,
some of their latest work concerned NF-κB dimer formation and
the role of IκBβ as a stabilizer [40], and the role of Toll/interleukin-
1 receptor-domain-containing adapter-inducing interferon-β
(TRIF) as a posttranscriptional regulator of TNFα [41].
The NF-κB signaling response is not homogenous through-
out the population, and distinct subpopulations have been
detected within the same experiment [42]. Both Tay et al.
and Turner et al. have shown that not all cells respond to
low concentrations of TNFα, and that this is probably due to a
heterogonous digital process. IKK (the inhibitor of IκB) needs
multiple phosphorylation steps to become activated, which
could lead to a digital cellular response profile [43,44].
In the modeling approaches, some groups have included only
parts of the NF-κB network that are sufficient to explain the
dynamical behavior measured in in vitro experiments [45–48] or
have developed methods to reduce complex models [49].
Krishna et al. [45] showed that three ODEs with a negative feed-
back loop are sufficient to simulate the observed oscillatory
behavior. Zambrano et al. [48] also developed a relatively simple
model with 11 ODEs and 14 parameters. They demonstrated that
the observed shape of oscillations amongst different experimen-
tal conditions and cell types (e.g. spiky or smooth) could all be
achieved in their model by varying multiple internal parameters
of their model by maximally a factor two [48].
The NF-κB pathway is difficult to fully grasp. Many modeling
studies have been performed and over and over again, the
system turns out to be more complicated than expected. This
is because the pathway is highly nonlinear, has multiple posi-
tive and negative feedback loops, and acts as an information
hub, receiving and passing on information to many other path-
ways. NF-κB pathway models have to our knowledge not been
applied to liver cell data. Instead, most models have been
applied to immune cells, because the cytokine TNFα is impor-
tant for regulation of the immune response and is itself regu-
lated by NF-κB. For the future application of NF-κB models in
DILI research, it should be kept in mind that cell types differ in
the cytokines they produce and respond to. Indeed, the liver is
a complex organ consisting of multiple cell types, all respond-
ing differently to cytokines such as TNFα [50].
2.3. Unfolded protein response pathway
The endoplasmic reticulum (ER) is the main organelle to fold
polypeptides or misfolded proteins toward structures with their
particular functions [51]. The ER is equipped with three main
signaling branches to cope with stress when un- or misfolded
proteins (i.e. the ‘controlled variable’) accumulate due to inter-
nal or external perturbations like aging [52] and drug treat-
ments. Collectively, these branches are known as the unfolded
protein response (UPR). In normal situations, when an overload
of ER stress becomes intolerable for a cell, its intracellular net-
work invokes the pathways for apoptotic death to prevent
adverse events at tissue level [51]. Malfunctioning of the ER
stress pathway can lead to prevailing apoptosis-promoting
actions instead of survival, i.e. an imbalance that can also result
in liver injuries [53].
2.3.1. Mechanism
Three transmembrane proteins have the ability to sense the
presence of unfolded proteins: inositol-requiring enzyme 1
(IRE1), Protein kinase RNA-activated-like ER kinase (PERK), and
activating transcription factor 6 (ATF6) (Figure 2C). In the
absence of ER stress, each of these three proteins forms a
complex with the binding immunoglobulin protein (BiP).
Upon ER stress, BiP molecules dissociate from the three sensors
and act as molecular chaperones of unfolded proteins, promot-
ing their correct folding. The dissociation will also trigger reg-
ulatory mechanisms in each of the three branches: In the first
UPR branch, free IRE1 molecules dimerize and auto-transpho-
sphorylate [54]. This activation leads to alternative splicing of
X-box binding protein 1 (XBP1) mRNA [55]. This mRNA activates
the XBP1’s transcription factor, which is responsible for the
regulation of genes involved in quality control of proteins, in
the degradation of misfolded proteins, and in ER expansion. In
the second branch, free PERKs first form dimers [56]. Then, PERK
dimers phosphorylate the α subunit of eukaryotic initiation
factor 2 (eIF2α). Phosphorylated eIF2α on the one hand attenu-
ates general translation [57] and on the other hand activates
the transcription factor ATF4. In the third branch, ATF6 first
translocates to the Golgi apparatus membrane and gets cleaved
[58]. This releases a cytosolic 50-kDa domain that operates as a
transcription factor (i.e. cleaved ATF6 [ATF6f]) regulating quality
control of proteins. The three factors, i.e. XBP1, ATF4, and ATF6f,
enhance the production of BiP, which binds to newly synthe-
sized proteins to recover the cell from ER stress [51,59]. On the
other hand, the three factors also increase the translation of
CCAAT/enhancer-binding protein homologous protein (CHOP).
CHOP has a proapoptotic role yet also upregulates the growth
arrest and DNA damage-inducible protein (GADD34). GADD34
provides negative feedback by promoting the dephosphoryla-
tion of eIF2α, which restores the protein translation capacity as
soon as stress is alleviated [60]. Amongst these proapoptotic
and pro-adaptive pathway branches, a quantitative understand-
ing of the cooperation between the branches is still lacking.
2.3.2. Modeling
A previous review [61] focused on both static and dynamical
models for the optimization of industrial protein production,
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including UPR models. Here, we review dynamical features of
the UPR and existing models including reaction kinetics, cross
talk between the three branches, and potential links to death
pathways. A simple dynamical model of the UPR involved a
linear system with separate proapoptotic (CHOP/GADD34) and
pro-adaptive (BiP) variables [62]. Simulation results showed a
faster transient response of the proapoptotic variable than the
pro-adaptive one, which is in agreement with experimental
observations. Other kinetic models of the ER stress pathway
have employed nonlinear chemical reactions. First, to improve
our understanding of the role of BiP binding to IRE1, the
mechanism to sense ER stress by IRE1 was investigated in a
detailed dynamical model [63]. Together with experimental
validation, it was demonstrated that BiP provides a buffer for
inactive IRE1 molecules, thus regulating IRE1 activity and pro-
tein folding homeostasis. Second, several studies investigated
the IRE1 and PERK branches of the UPR and the role of
attenuation of translation when there is repeated exposure
to ER stress [64,65]. An example of such repeated exposures
naturally occurs in secretory cells, e.g. pancreatic β-cells, in
which highly variable patterns of blood glucose level cause
high-frequency pulses of insulin production that are processed
by the ER. Type 2 diabetic patients often exhibit irregularity of
insulin pulsatility [66]. The modeling studies showed that
attenuation of translation is beneficial for cells in case of
repeated exposure [64], yet becomes dispensable in case of
a high-frequency stress-induced stimulus [65]. With respect to
the observed irregularity of insulin pulsatility, this model
offered a tool to further investigate the potential role of UPR
in diabetes.
More recently, computational models incorporating all three
UPR branches have been constructed [24,67]. Mathematical
analysis on one of these models has revealed three distinct
types of dynamical behaviors of CHOP [24], i.e. transient activa-
tion, sustained oscillations, and elevated activity. Interestingly, a
parameter regime with oscillations in CHOP and also in the
eIF2α-mediated attenuation of translation was identified in
these simulations. To date, such oscillations have not been
observed in experiments, which could mean that the para-
meters for the oscillatory regime are not biologically realistic.
These dynamical models will be useful in future exploratory
studies looking into cross talk amongst the three branches.
Apart from investigating the intrinsic complexity of the
biochemical network, ER stress models have been exploited
to understand how different types of pharmaceutical agents
induce ER stress, which can rely on different mechanisms.
For example, dithiothreitol (DTT) breaks the disulfide bonds
of proteins, while thapsigargin (TG) depletes Ca2+ from the
ER [68], thus reducing the ER’s capacity to fold newly trans-
lated polypeptides. In one modeling study [65], the bond-
breaking stress, e.g. induced by DTT, was considered to
function in an additive way with the basal influx rate of
new unfolded proteins, while the translation stress as e.g.
induced by TG was considered to function in a multiplicative
way with that rate. In order to study the role of translation
attenuation (by phosphorylated eIF2α), two model variants
were studied: one with translation attenuation upon expo-
sure to stress and one without such attenuation. Both for
translation stress (like TG) and for chemical stress (like DTT),
the simulations revealed a stronger reduction of the amount
of unfolded proteins in the presence than in the absence of
translation attenuation. Moreover, this beneficial role of
translation attenuation was most prominent for translation
stress. As a final contribution of modeling studies to the
understanding of the UPR, the effects of ER stressors on
cell death have been investigated. Erguler et al. [24] inte-
grated their ER stress pathway model with a previously
constructed apoptosis module [69] via bcl-2-like protein 4
(also known as BAX)/Bcl-2 homologous antagonist/killer
(also known as BAK1) in mitochondrial membranes. In the
model, the CHOP activity represented the stress variable.
This study demonstrated that a preconditioning stress at a
mild level can suppress the apoptotic signal (i.e. BAX) for
subsequent ER stress, since BiP molecules already accumu-
late sufficiently. Further modeling studies combined with
quantitative data on UPR activation and cytotoxicity mea-
surements are likely to advance our understanding of the
role of ER stress in inducing or preventing cell death.
Moreover, integrating such (intra)cellular models into com-
putational models at a larger biological scale will help to
better predict DILI in the future.
2.4. HSR pathway
A common environmental perturbation, heat shock, i.e. an
elevated temperature, can denature proteins, potentially lead-
ing to proteotoxicity. Upon such heat shock, heat-shock pro-
teins (HSPs) act as molecular chaperones that bind to
denatured proteins (i.e. the ‘controlled variable’) and recover
those into folded structures [70]. The resulting transcriptional
and (post)translational processes are collectively termed the
HSR (Figure 2D) and malfunctioning of the HSR can be
involved in DILI [71,72].
2.4.1. Mechanism
HSPs occur in both the cytosol and in various organelles to
assist protein folding (e.g. BiP in the above-mentioned ER
stress pathway is also a HSP). In unstressed situations, HSPs
bind to heat-shock transcription factors (HSFs), amongst which
HSF1 is the major one [73]. When large numbers of denatured
proteins compete with HSF1 for binding to HSP, HSF1 mono-
mers form dimers and trimers. Subsequently, HSF1 trimers
bind to the heat-shock sequence element and activate the
HSP encoding gene. This leads to increased transcription of
HSPs which bind to remaining denatured proteins to resolve
the stress [70]. As discussed above, the multimerization of
HSF1 monomers increases the gain of the response, thus
strengthening the protective capability to small thermal fluc-
tuations [20].
2.4.2. Modeling
Dynamical models of the HSR have been built and studied
extensively with data sets in hyperthermia conditions. One
biologically and physiologically relevant aspect of the HSR is
the development of tolerance, i.e. the ability of a cell to
become resistant to heat stress following a mild exposure to
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heat shock [70]. To understand this tolerance, Peper et al. [23]
employed a basic model of HSR dynamics, which was in good
agreement with observations in Reuber H35 rat hepatoma
cells with both single and double heat-shock stimuli. Petre
et al. [74] constructed a more detailed model incorporating
components describing HSP-regulated transcription. They per-
formed a sensitivity analysis to minimize the model by identi-
fying and eliminating model components that only have
marginal effects. Moreover, Scheff et al. [75] considered the
effect of temperature changes on the transcriptional and mul-
timerization processes. The above models could not capture
data sets in different experimental conditions, yet after exten-
sion of the model by Petre et al. [74], a wide spectrum of data
sets from HeLa cells were described well. From a local sensi-
tivity analysis at steady state, this work also showed that the
initial amount of HSF is expected to affect the stress-induced
damage outcome much more than the amount of initial HSP
and denatured proteins.
One of the HSFs, i.e. HSF2, is a key factor in developmental
processes such as oogenesis, spermatogenesis, and cortico-
genesis [76]. HSF2 can cooperate with HSF1 by forming active
heterotrimers in response to heat shock. A recent computa-
tional study employed probabilistic formulations revealing
that the ratio of two HSF2 isoforms arising through alternative
splicing controls the HSF1 transcriptional activity within indi-
vidual cells [77]. However, no dynamical model has incorpo-
rated these recently proposed heterotrimeric processes, which
might be explored when time-course data sets of the HSR
become available during different HSF2-related developmen-
tal phases. As most models have been applied to experimental
settings with thermal perturbations, linking of these models to
drug-induced stress via HSP pathways needs to be further
explored for its relevance to DILI in the future.
2.5. DNA damage response pathway
DNA damage can be caused both by endogenous processes,
like deamination or replication errors, and by exogenous pro-
cesses, like radiation and drugs. Drugs can cause DNA damage
either directly or indirectly: Some drugs (mostly chemothera-
peutics) directly intercalate between or covalently bind to
DNA [78]. Other drugs lead to ROS that can bind to DNA
and cause DNA damage, thereby indirectly activating the
DNA damage response pathway [33,79–82]. When the DNA
damage is not properly repaired, it can ultimately lead to
cancer. Due to the relevance in cancer research, this pathway
has been investigated in great detail, which includes modeling
studies with the stressor γ-irradiation [25,83–97].
2.5.1. Mechanism
There are many different types of DNA damage, ranging from
simple base substitutions to double-strand breaks (DBs). In this
stress pathway, some form of DNA damage is the ‘controlled
variable’ that activates the system, and activation of the path-
way will lead to DNA repair. Because different types of
damage need a different type of repair response or cell fate,
the DNA damage response pathway consists of multiple mod-
ules, each dealing with different types of DNA damage [82].
One of the key elements (the transcription factor) of the path-
way is the tumor suppressor p53 (Figure 2E), yet its activation
can lead to different outcomes: The cell will try to repair the
DNA damage, but to prevent further damage, it can also lead
to permanent cell growth arrest (senescence) or apopto-
sis [98].
2.5.2. Modeling
Both p53 and mouse double minute 2 homolog (Mdm2), a
negative regulator of p53, oscillate after getting stressed by
DBs caused by γ-irradiation, both on population [83] and on
single-cell level [99]. Lev Bar-or et al. [83] developed a minimal
model of the interaction between p53 and Mdm2 to describe
these oscillations. The transcription factor p53 stimulates the
production of Mdm2, while Mdm2 enhances the degradation
of p53, creating a negative feedback loop leading to an oscil-
lation of both proteins when DNA damage is present. The
oscillatory behavior only comes to a halt when the damage
is repaired or is so excessive that the cell goes into apoptosis.
Lev Bar-or et al. [83] argue that high levels of p53 are needed
to activate the downstream DNA repair targets in adequate
levels, yet continuously high levels of p53 induce apoptosis.
Thus, oscillations give the cell the best chance to survive [83].
Not only p53 and Mdm2 oscillate after γ-irradiation, but
also the active forms of the upstream regulators ataxia telan-
giectasia mutated (ATM) and checkpoint kinase 2 (Chk2) pul-
sate, and these pulses are required for p53 oscillations.
Batchelor et al. [85] therefore proposed a model in which
ATM and Chk2 activate p53 which subsequently activates
(besides Mdm2) wild-type p53-induced phosphatase 1
(Wip1). Wip1 provides negative feedback in the pathway by
inhibiting ATM and Chk2. The origin of the pulsation of both
ATM and Chk2 is ongoing DNA damage, which keeps reacti-
vating ATM and Chk2 after deactivation by p53 [85]. In a
follow-up study, Batchelor et al. [84] showed that UV light
instead of γ-irradiation also triggers p53 but is then regulated
by different upstream targets: Whereas γ-irradiation triggers
ATM and ATM triggers Chk2, UV light triggers ataxia telangiec-
tasia and Rad3-related protein (ATR) and ATR triggers Chk1.
Because ATR is not inhibited by Wip1, this results in a different
response curve: after stimulation with UV light, p53 pulses
only once [84].
Ma et al. [91] constructed a model that also included DNA
repair itself i.e. consisting of three elements: a module about
DNA damage and repair, a detector module, and an oscillator
module. DNA damage and repair were modeled in a stochastic
fashion, because the number of DBs at a low γ-irradiation level
is very low. Specifically, DNA damage was described using a
Poisson distribution based on the γ-irradiation level. Similarly,
repair of DBs by DNA repair complexes was described by
incorporating the amount of time needed to fix a DB as a
stochastic variable. The DNA repair complexes also activate
the second module, i.e. the detector of the system (ATM). ATM
autoregulates itself in a positive feedback loop and activates
the oscillators p53 and Mdm2. The added stochasticity ensures
that there is some variability between individual cells. As a
result, this modeling [91] showed that ongoing oscillations
within individual cells can translate into the damped
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oscillations at the population level as observed experimentally.
Moreover, variability in pulse number between cells has been
confirmed in in vivo experiments [99].
An important cellular decision upon DNA damage is the
fate of the stressed cell. When damage can still be repaired,
the cell temporarily arrests the cell division process, and when
the damage is too severe, the cell either goes into senescence
or apoptosis. In cancer cells, p53 is often mutated, so despite
substantial DNA damage, cells can continue to grow and
divide. Some modeling efforts have been undertaken to inte-
grate the DNA damage response dynamics with the decision
to repair the DNA damage or to go into senescence/apopo-
tosis. For example, Dolan et al. [25] successfully integrated two
models, one that simulated senescence [92] and one that
focused on damage repair [88]. The combined model captures
a mechanistic overview of the DNA damage repair response,
p53 signaling, and cell fate and predicts which dose of γ-
irradiation leads to senescence. One of the clinically relevant
findings was that repeated low doses of irradiation are as
effective as a single high dose to steer cells into senescence,
although the model overpredicted the effect of repeated low
doses [25]. To our knowledge, p53 modeling has not been
specifically applied to the liver and thus represents an impor-
tant next step in DILI research.
2.6. Apoptosis pathway
Apoptotic cell death is a form of programmed cell death. It
makes sure cells are destroyed in an organized manner, with-
out losing the structure of the surrounding tissue [100] or
bringing harmful molecules in its environment that could
trigger inflammation [21].
2.6.1. Mechanism
Caspases are the primary agents of apoptotic cell death. They
are a family of proteases that are inactive under homeostatic
conditions. Caspases can be categorized in two groups, initia-
tors and effectors. Initiator caspases are responsible for acti-
vating other caspases and amplifying the detected signal (i.e.
the sensor of the system), while effectors are responsible for
the dismantling of the cell. Initiation of the caspase pathway
happens through either cell-extrinsic or -intrinsic stimuli. Cell-
extrinsic signaling originates from outside the cell and is
picked up by ‘death receptors’ located on the cell surface
membrane, which dimerize and activate initiator caspase-8
or -10, which in turn activates effector caspase-3. The cell-
intrinsic pathway starts in the mitochondria with mitochon-
drial outer membrane permeabilization: cytochrome c release
from the mitochondrial intermembrane space into the cyto-
plasm leads to dimerization and activation of initiator caspase-
9, which as before activates the effector caspase-3 [100]. The
intrinsic apoptosis pathway can be activated by a wide variety
of internal stressors, some discussed above like DNA damage
and ER stress [101]. Therefore, the intrinsic pathway is the
most important death pathway for DILI. Because apoptosis
pathway modeling has already been often and extensively
reviewed [101–108], we here focus on the highlights and its
relevance to DILI.
2.6.2. Modeling
Several modeling studies have increased our understanding of
apoptosis. Fussenegger et al. [109] published a model that
included both cell-extrinsic and intrinsic death signaling. They
used the model to test the potential for therapies inhibiting the
apoptosis pathway, specifically applied to patients that have
diseases in which cells are hypersensitive to apoptosis like
Alzheimer (note though that caution should be taken when
tempering with the apoptosis pathway because it safeguards
us from for example cancer development). In the simulations,
procaspase blocking was shown to be effective to prevent
death through external signaling stimuli, but in silico, cells
could still die from cytochrome c release due to internal signal-
ing. Thus, because the cell has two distinct pathways, both
should be blocked to guarantee that cells do not die from
apoptosis. The model analysis further demonstrated that there
exist a large number of redundant control mechanisms in the
cell-intrinsic, but not in the cell-extrinsic caspase pathway. The
general lack of control of the cell-extrinsic pathway may imply
that this is in fact a ‘death override,’ which could explain why
perfectly healthy cells go into apoptosis [109].
Eissing et al. [110] analyzed the bistability of the caspase
cell-extrinsic pathway, because this is a mandatory property of
the apoptotic pathway: On the one hand, cells should be
resistant against minor fluctuations in signal in order not to
trigger apoptosis by accident. On the other hand, when a cell
is prompted into apoptosis, it should not be possible to revert
back. The simplified model of the extrinsic pathway consisted
of only six ODEs and considered stress to activate caspase-8,
which subsequently activates caspase-3. Activated caspase-3
activates the remaining inactive caspase-8 molecules in a
positive feedback loop. Moreover, active caspase-3 activates
inhibitor of apoptosis (IAP, a member of a family of inhibitors
of executioner caspases), which subsequently binds to active
caspase-3 after which both get targeted for degradation. In
their bistability analysis of this simple model, the ‘alive’ stage
of the cell was unstable for biologically reasonable parameter
values, implying that cells would go into apoptosis with only a
little bit of noise. Eissing et al. [110] therefore suggest that
caspase-8 needs a similar negative feedback loop as caspase-3
has via IAP. In the case of caspase-8, this role could be played
by bifunctional apoptosis regulator (BAR), i.e. active caspase-8
activates BAR that binds to active caspase-8 after which both
get targeted for degradation. These new model assumptions
were sufficient to obtain robust bistability [110].
Chaves et al. [111] combined an NF-κB model [112] with
the above-mentioned caspase model [110]. Because the con-
nectivity between the NF-κB pathway and the caspase path-
way is not completely understood, they added two known
connections and tested various suggested but unconfirmed
connections between the two models. The two know connec-
tions involve targets of NF-κB, i.e. NF-κB regulates both IAP
and FLICE-inhibitory protein (FLIP). IAP as mentioned above
inhibits active caspase-3, while FLIP inhibits an upstream tar-
get of caspase-8. When simulating the combined model with
the two known links, it was apparent that a feedback mechan-
ism was needed, to downregulate NF-κB upon caspase activa-
tion. Three feedback loops back from the caspase pathway to
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the NF-κB pathway were tested in the simulations. Inhibition
from active caspase-3 on NF-κB indirectly via IKKα was most
consistent with experimental observations. Thus, this analysis
demonstrates how modeling can help to understand the links
between stress (and death) pathways [111].
Linking activity of stress pathways to death pathways is an
important step to obtain valuable insights into DILI. Cell death
could be used as a risk indicator of the harmful effects drugs
can have on the liver. Some of the above-discussed examples
taking a first step in this direction (though not applied to the
liver) include the prediction of cellular senescence upon DNA
damage [25] and the effect of ER stress [24] or NF-κB activa-
tion [111] on apoptosis. Ultimately, different types of drugs
and the associated activation patterns of diverse stress path-
ways need to be linked to cytotoxicity and to liver damage.
3. General discussion
Toxicity frequently occurs in the liver, because this organ is
responsible for breaking down many xenobiotic compounds.
Although many models have been developed for toxicity
pathways, currently there are only a few models specifically
designed for liver cells. As discussed, Leclerc et al. adapted a
general oxidative stress model to describe liver cell dynamics
[22]. The question arises whether all dynamical models
designed for a particular organ or cell line can be applied to
a different organ, in our case the liver. The underlying
mechanisms of the stress pathways are likely to be highly
similar amongst most cell types. The basic structure of the
model can therefore be applied to different organs and cell
types. However, some underlying system parameters, which
are considered to be constant within a model, might differ
between cell lines or cell types and so should be reevaluated.
For example, Basak et al. [113] argue that their inflammatory
stress pathway model can be adapted to other cell lines, after
which some parameters need to be reset. Parameters based
on the biophysical characteristics of the molecule such as the
binding efficiency are unlikely to differ between cells, while
other parameters can be affected by cell type-specific pro-
cesses [113]. For example, the transcription rate of a gene
could differ between cell lines due to chromatin regulation.
As a second example, consider a protein (X) that strongly
affects the binding of two other proteins (Y and Z), but
whose expression is itself not modulated by the pathway.
The pathway dynamics of two cell lines with either low or
high expression of protein X can then be described by a
model that does not explicitly consider protein X, albeit with
different parameters for the interaction between proteins Y
and Z. In conclusion, having a model that already describes
the mechanism of the stress pathway of interest, although
designed for very different cells, typically can be reused for
other organs. Nevertheless, some parameters will need to be
measured or fitted again. As already mentioned above,
Zambrano et al. [48] showed that their simple model of NF-
κB signaling could reproduce different types of oscillations,
depending on values of their system parameters. They argue
that the different behaviors observed in in vitro experiments
are likely the effect of using different cell lines. This indeed is
consistent with the hypothesis that adjusting the parameter
values is often sufficient to reuse a model for a different tissue
or cell line. The oxidative stress model by Leclerc et al. [22]
focuses on the effect of a single drug and its mechanism of
action. To be able to evaluate if drugs are potentially harmful
to the liver, we need a model that is sufficiently general to be
employed for many different drugs. Thus, such a model should
take into account that drugs can activate a stress pathway in
different ways. For example, the ER stress model by Trusina
and Tang [65] was used to study the effect of different types
of ER stress (translational and bond-breaking stress) on the
dynamics of the UPR. Similarly, for the case of oxidative stress,
metabolites can in some cases directly bind to cysteines on
Keap1, or they can lead to increased ROS formation in mito-
chondria [27]. Moreover, different drugs preferentially bind to
different cysteine sites on Keap1 and might therefore have a
different effect. In conclusion, for the evaluation of drugs that
are potentially harmful to the liver, we need models that are
specifically adapted for the liver and that are applicable to
different drugs.
To be of direct relevance to DILI, in the end, predictions
by pathway models need to be made at an organ rather
than cellular level. Insights gained by dynamical pathway
models applied to the cellular level based on cell cultures
may well be applicable to the human liver, but this is not
necessarily straightforward because liver cell cultures are not
fully representative of in vivo cellular behavior [114]: First,
metabolism of drugs is typically poorly developed in cell
lines compared to the in vivo situation, which may be pro-
blematic in case the metabolized form rather than the par-
ent drug is the harmful compound. Second, multiple cell
types may have a role in the development of adverse
effects, e.g. during an inflammatory response. Solutions for
these problems are being developed: Currently, in vitro toxi-
city tests are often done within (2D) cell monolayers. Newer
methods apply toxicity tests on cell spheroids within 3D
matrix gels and these have an improved drug metabolism
compared to their 2D counterparts [114]. Progress is also
made in cell cultures consisting of multiple cell types [115],
and organ-on-a-chip approaches represent another promis-
ing solution [116].
One of the important issues when developing an ODE-
model is the model size. Researchers often include a lot of
detail of the signaling pathway they have studied. Basak et al.
[113] have argued that the reasons for misregulation of a
pathway and also potential therapeutic targets are often out-
side of the modeled part of the pathway. Therefore, in order to
find therapeutic targets, larger models may indeed need to be
studied. However, an overly complex model with many ODEs
and parameters requires complicated analysis techniques and
may lead to overfitting, whereas simpler models designed
from first principles may just as well be able to describe
experimental observations [48]. Moreover, for the specific
application of DILI, small models may be sufficient to find a
threshold at which potentially harmful compounds cause
damage [113].
One option to deal with model complexity is to test new
network hypotheses by studying subparts of a larger model. A
good example of this approach is a study by Hofmann and
coworkers on their NF-κB modeling [40]. Specifically, they
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tested different hypotheses on NF-κB homo- and heterodimer
formation, initially with a very minimal model. They expanded
the model until it explained the experimental observations on
for instance dimer abundances. In the end, they altered their
already well-established complex model, to include their new
findings on dimer formation, and see if it still exhibits the
same dynamics [40]. Another option to deal with model com-
plexity is to first construct a complex model and employ
reduction algorithms (e.g. [49]), which helps to determine
the key processes involved in shaping the dynamics.
As discussed, cross-links between stress pathways and
death pathways exist and are important to investigate in
order to understand the relation between stress pathway
activation and cell fate. One approach to obtain more
insight is by linking models for these different pathways,
but this also adds to the model complexity. Apart from
cross-links between stress and death pathways, also the
various stress pathways themselves are intertwined. For
example, there is a suspected link between the oxidative
and inflammatory stress pathways. One of the target genes
of Nrf2 produces heme oxygenase 1 (HMOX1). HMOX1 upre-
gulation can lead to inhibition of NF-κB-mediated transcrip-
tion [117]. Indeed, activation of Nrf2 by some drugs (e.g.
carbamazepine) inhibits the NF-κB response, yet not all
drugs (e.g. acetaminophen) that activate Nrf2 have this
effect on the NF-κB response [118]. The HMOX1 gene is
also regulated by the transcriptional repressor BTB domain
and CNC homolog 1 (BACH1) that inhibits under unstressed
circumstances the binding of Nrf2 to the HMOX1 gene [119].
Thus, HMOX1 and BACH1 likely represent a selective cross-
link between two of the discussed stress pathways.
Investigating the relations between stress pathways is
needed for a full mechanistic understanding of adverse
effects. However, a complicating factor is that cross links are
not always activated and might be compound specific. We
propose two methods to overcome this problem. As a first
approach, the activation of all stress pathways upon exposure
to a specific drug can be measured in vitro to determine which
stress pathway models to use for this drug. This can for
example be done in cell lines with built-in fluorescent repor-
ters for the sensor, transcription factor, and downstream tar-
gets during live microscopy imaging [11]. For example, Wink
et al. showed that known DILI drugs are frequently stress
pathway specific, but some induce multiple stress pathways
at a molecular level. The second, more challenging approach
to take pathway cross talk into account is to create a general
model that includes multiple relevant pathways and cross-
links based on data in which the expression of proteins that
are suspected to have a role in the cross talk is altered.
However, this is an ambitious effort, which needs to start
with the construction of suitable models for the individual
pathways.
4. Expert opinion
The combination of in vitro testing of drugs on human cell
lines, dynamical pathway modeling, and PK and PK–PD mod-
eling have the potential to become a relevant screening
method in order to detect DILI compounds at an early stage
of drug development: In this procedure, cell lines are first used
to assess the effects of compounds on relevant stress path-
ways within cells and cell fates such as death and proliferation
arrest. This information is exploited to optimize and validate
dynamical models describing these pathways. Subsequently,
the models describe the effect of a compound on different
pathways and cell fate in order to subsequently predict the
tolerable dose. Finally, PK and PK–PD modeling are employed
to translate this threshold to a corresponding tolerable drug
intake in humans. This process was illustrated by Leclerc et al.
[22] who integrated their dynamical model of the oxidative
stress pathway with a PK model predicting how much of the
drug actually reaches the cell. Experimental measurements
were performed with an organ-on-a-chip setup, and the PK
model described the amount of the drug flowing into the
extracellular compartments, taking into account adsorption
and desorption rates. Both the PK model and the oxidative
stress model included a system variable to represent the
amount of drug within the cell, which was used to bridge
the two models. This approach facilitated the quantification of
the effect of drugs added to the organ-on-a-chip on the stress
induced to cells. In the future, such a strategy can be applied
to other DILI-related drugs and different stress pathways.
This procedure is likely to work especially well for drugs
that cause intrinsic DILI because they are expected to have a
threshold with a similar range for different patients. Drugs that
cause idiosyncratic DILI are hard to predict because of their
low incidence rate. It could therefore be that the proposed
combination of in vitro screening and computational modeling
will not be successful in predicting idiosyncratic DILI until we
have a better understanding of why these drugs are harmless
to the majority of people but cause such extreme injuries in a
few. An additional problem is that it is unlikely that in vitro cell
lines react in the same way as cells within a patient, e.g.
because additional perturbations are absent that naturally
occur in patients, like cytokines that trigger immune
responses.
Nevertheless, in order to improve our ability to detect
idiosyncratic drugs, we need to obtain a quantitative under-
standing of the mechanism by which these drugs interact with
the various stress and death pathways involved in liver injury.
For example, drugs may alter the functioning of a stress or
death pathway instead of merely activating it. Although this
may be acceptable under some conditions, exposure to addi-
tional stress factors may lead to an unpredicted effect. Thus,
focussing on the detection of altered pathway dynamics might
give valuable clues to predict idiosyncratic drugs. Dynamical
modeling is expected to have a pertinent role in this research.
To classify potential harmful drugs, it is important to deter-
mine which stress and death pathway is related to DILI. In vitro
data can be employed to screen which stress and death path-
ways are activated by specific drugs. Furthermore, they are
needed to parameterize and validate dynamical models. To
this purpose, one of the most important factors includes how
the behavior evolves over time. Thus, having measurements
throughout the experiment, and not just end point measure-
ments, is essential. Currently available methods include the
14 I. A. KUIJPER ET AL.
use of reporter cell lines, in which the stress or cell death
pathways can be monitored over time. In contrast to end-
point assays, live confocal microscopy gives the opportunity
to measure single-cell behavior over time [11].
In conclusion, to classify potentially harmful drugs, it is impor-
tant to determine which stress and death pathways are related
to liver injury. In vitro testing approaches can be employed to
screen whether drugs activate or alter stress pathways. The
development and application of in vitro tests and a quantitative
understanding of the mechanisms behind stress and death path-
ways through dynamical pathway modeling together offer a
promising prospect for DILI research in the years to come.
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